Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

JNJ Stock - Johnson Johnson Stock Trading


home / stock / jnj

JNJ JNJ Quote JNJ Short JNJ News JNJ Articles JNJ Message Board

MWN AI Summary *

Johnson & Johnson (NYSE: JNJ) is a globally recognized healthcare company known for its diverse product portfolio, which includes pharmaceuticals, medical devices, and consumer health products. Founded in 1886, J&J has established itself as a leader in multiple sectors of the healthcare industry, making it a staple in both consumer and institutional investment portfolios.

The company operates through three main segments: Pharmaceutical, Medical Devices, and Consumer Health Products. In the Pharmaceutical sector, J&J has made significant strides with innovative drugs, particularly in immunology, oncology, and neuroscience. Recent approvals and advancements in their drug pipeline have positioned the company as a formidable player in the biopharmaceutical industry.

J&J's Medical Devices segment encompasses a wide range of surgical instruments, orthopedic devices, and interventional solutions. This division has shown resilience and growth potential, particularly with advancements in minimally invasive surgical technologies and digital health solutions.

On the consumer health side, J&J offers well-known brands such as Tylenol, Neutrogena, and Band-Aid, which contribute to its reputation and stability. Despite increased competition and market pressures, the company's focus on research and development has allowed it to maintain strong brand loyalty and consumer trust.

In recent years, J&J has faced challenges, including litigation related to its opioid crisis involvement and safety concerns surrounding some consumer products. However, the company has actively taken steps to address these issues while continuing to invest in its growth strategy.

Financially, J&J has demonstrated consistent revenue growth and dividend reliability, making it a popular choice for income-focused investors. As of late 2023, J&J is well-positioned to adapt to evolving market dynamics and leverage its extensive resources to drive future growth while fulfilling its commitment to healthcare innovation.

MWN AI Analysis *

Johnson & Johnson (NYSE: JNJ) stands as a resilient player in the healthcare sector, offering a diversified portfolio that includes pharmaceuticals, medical devices, and consumer health products. This diversification serves as a shield against industry volatility, allowing JNJ to maintain a strong market position even amid economic uncertainties.

As of October 2023, JNJ has demonstrated robust financial performance. The company reported a consistent increase in its revenue driven primarily by its pharmaceutical division, which includes key products such as Darzalex and Imbruvica. The ongoing innovation in drug development, bolstered by a strong pipeline, positions JNJ favorably for sustained growth. Furthermore, with recent advancements in immunology and oncology, the potential for breakthrough therapies could provide significant upside to revenue in the coming years.

Another aspect to consider is JNJ's commitment to shareholder value. The company has a long history of dividend payments and has been consistently increasing its dividend, making it attractive for income-focused investors. As of Q3 2023, JNJ's dividend yield remains competitive compared to industry peers, adding to its appeal as a stable investment option.

However, potential investors should be mindful of the inherent risks. JNJ faces challenges related to product litigation, particularly concerning its talc-based products and opioid litigation. Such legal issues may pose financial and reputational risks in the long term. Additionally, the healthcare sector, while currently robust, is subject to regulatory shifts that could impact profitability.

In conclusion, JNJ is a solid stock for those looking to invest in a healthcare giant with a strong market presence and consistent dividend performance. Nevertheless, potential investors should weigh these strengths against the lingering risks in the legal landscape and the dynamic regulatory environment. A balanced approach, viewing JNJ through the lens of both stability and risk, is advisable for prospective investors.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors.

Quote | Johnson & Johnson (NYSE:JNJ)

Last:$162.98
Change Percent: 0.97%
Open:$163.18
Close:$162.98
High:$164.7
Low:$162.297
Volume:11,011,302
Last Trade Date Time:07/17/2025 03:41:44 pm

News | Johnson & Johnson (NYSE:JNJ)

  • Johnson & Johnson: The Worst Is Baked In

    2025-07-17 12:40:26 ET Company Background Johnson & Johnson ( JNJ ) is the second largest pharmaceutical company in the world by market capitalization at $377B. The company has two operating segments: Innovative Medicine and Medical Devices. Innovative Medicine is engage...

    • July 17, 2025 12:40:26 pm

    • |
    • SeekingAlpha
    • |
      • JNJ Stock
      • JNJ Quote
      • JNJ Short
      • JNJ News
      • JNJ Articles
      • JNJ Message Board
  • Buy Recommendation Issued On JNJ By UBS

    2025-07-17 10:15:09 ET UBS analyst issues BUY recommendation for JNJ on July 17, 2025 12:43PM ET. The previous analyst recommendation was Buy. JNJ was trading at $162.74 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst rec...

    • July 17, 2025 10:15:09 am

    • |
    • KlickAnalytics
    • |
      • JNJ Stock
      • JNJ Quote
      • JNJ Short
      • JNJ News
      • JNJ Articles
      • JNJ Message Board

Message Board Posts | Johnson & Johnson (NYSE:JNJ)

Subject By Source When
znewcar1: $JNJ taps 166. MH167.23 a BO186 HH znewcar1 investorshangout 04/14/2023 7:58:15 PM
Holding Big Pharma ACCOUNTABLE: J & J To Agoura Guy investorshub 04/12/2023 1:41:45 AM
whytestocks: $JNJ News Article - Why Johnson & Johnson Stock Was Climbing Today whytestocks investorshangout 04/05/2023 7:50:45 PM
whytestocks: $JNJ News Article - Traders Weigh Signs of Weakening Job Market, Shares Fall whytestocks investorshangout 04/05/2023 3:35:47 PM
whytestocks: $JNJ News Article - Better Dividend Stock: AbbVie vs. Johnson & Johnson whytestocks investorshangout 04/05/2023 2:30:45 PM

MWN AI FAQ **

What are the recent financial performance trends for Johnson & Johnson JNJ, and how do they compare to industry benchmarks?

As of October 2023, Johnson & Johnson has shown steady revenue growth and improved margins, outperforming industry benchmarks in the pharmaceutical sector while facing challenges in consumer health, indicating a mixed but generally positive financial performance trend.

How is Johnson & Johnson JNJ addressing the legal challenges related to its talc-based products in terms of financial impact and brand reputation?

Johnson & Johnson is addressing legal challenges related to its talc-based products by allocating significant financial resources for settlements and legal defense while simultaneously working to enhance brand reputation through transparency and a focus on safer product innovations.

What strategic initiatives is Johnson & Johnson JNJ pursuing to enhance its pharmaceutical division and drive growth?

Johnson & Johnson is focusing on strategic initiatives such as expanding its oncology pipeline, investing in innovative therapies like gene editing and immunology, and enhancing collaborations and acquisitions to drive growth in its pharmaceutical division.

How has Johnson & Johnson JNJ adapted its supply chain strategy in response to global disruptions and what implications does this have for future profitability?

Johnson & Johnson has diversified its supply chain by increasing local sourcing and investment in technology to enhance resilience against global disruptions, positioning itself to maintain profitability through improved efficiency and reduced reliance on vulnerable international suppliers.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get JNJ Alerts

News, Short Squeeze, Breakout and More Instantly...

Johnson & Johnson Company Name:

JNJ Stock Symbol:

NYSE Market:

0.97% G/L:

$162.98 Last:

11,011,302 Volume:

$163.18 Open:

$162.98 Close:

Johnson & Johnson Website:

Johnson & Johnson Logo

Ad

Investor Relations
RECENT JNJ NEWS
  • JNJ - Buy Recommendation Issued On JNJ By UBS

    2025-07-17 10:15:09 ET UBS analyst issues BUY recommendation for JNJ on July 17, 2025 12:43PM ET. The previous analyst recommendation was Buy. JNJ was trading at $162.74 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst rec...

  • JNJ - Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer

    Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer PR Newswire New Drug Application ...

  • JNJ - Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income

    2025-07-17 06:05:00 ET Johnson & Johnson (NYSE: JNJ) has been an extremely reliable dividend stock for decades. The healthcare behemoth has raised its payment for 63 straight years, including by 4.8% earlier this year. That places it in the elite group of Dividend Ki...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get JNJ Alerts

Get JNJ Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1